Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3558 in Advanced Solid Tumors
NCT04408079Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3558 in solid tumor (advanced stage), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose at 28 days, Adverse Events at 28 days and 2 more. Status: unknown.
02
Drugs
TQB3558
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04408079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04408079.